New antibiotic TQD3524 tested in kidney patients
NCT ID NCT06522945
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested a single dose of the antibiotic TQD3524 in 48 people with varying degrees of kidney function. The goal was to see how the drug moves through the body and is removed, especially by the kidneys, and to check for any safety issues. The study did not aim to treat infections, but to gather important information for future dosing guidelines.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TQD3524 (a polymyxin antibiotic)
- What this could lead to
- If successful, this study could help doctors understand how to safely dose TQD3524 in patients with kidney problems, potentially improving treatment for serious bacterial infections.
- What could go wrong
- This is a very early Phase 1 study with only 48 people, focused on drug levels and safety, not on curing infections. Results may not apply to all patients or lead to a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital)
Jinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk